Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
申请人:——
公开号:US20020045191A1
公开(公告)日:2002-04-18
The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.
本发明涉及旨在靶向HBx介导的Src激酶、Src酪氨酸激酶家族成员和Src激酶家族信号转导通路成分活化的治疗方案和药物组合物,用于治疗HBV感染及相关紊乱和疾病,如HCC。本发明进一步涉及针对 HBx 及其维持 HBV 复制所需的基本活动的治疗 HBV 感染的药物组合物。本发明部分基于申请人的发现,即 Src 激酶信号级联的激活在哺乳动物疱疹病毒复制中起着基础作用。申请人已经证明,HBx 介导了 Src 激酶家族的活化,而这种活化是 HBx 为哺乳动物疱疹病毒复制提供的关键功能。